Published in Cancer Weekly, February 10th, 2009
"We have evaluated a clinical grade, non-toxic analogue of polyl:C, poly(I:C12U) (Ampligen (R)), as a potential adjuvant for cancer immunotherapy, for its ability to drive maturation Of human myeloid DC. Our results provide evidence that poly(I:C12U) is effective in inducing optimal phenotypic (elevated levels of MHC-Class I/Class II, CD83, CCR7, CD86 and CD40...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.